Modest Gains and Extra Safety Flags Sink Cytokinetics After ESC Data
Detailed ACACIA results delivered statistical success without a bigger commercial or safety story.
/ 4 items
#CYTK↓
Cytokinetics’ Myqorzo Succeeds Where Camzyos Failed: Positive Phase 3 Results in Non-Obstructive HCM
Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
FDA Approves New Heart Drug MYQORZO for Obstructive HCM
The FDA has approved Cytokinetics' MYQORZO (aficamten), a groundbreaking treatment for adults with symptomatic obstructive hypertrophic cardiomyopathy to improve heart function and reduce symptoms.
Aficamten: A New Horizon for Hypertrophic Cardiomyopathy Treatment
Cytokinetics' experimental drug Aficamten demonstrates superior improvements in exercise capacity and cardiac function compared to standard care for obstructive hypertrophic cardiomyopathy, with a favorable safety profile across multiple studies.